Prostate Cancer | Specialty

Dr. Bradley on Exercise in Treatment-Related AE Management

November 16th 2018

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.

Dr. Parker on the Rationale for Radiotherapy in Metastatic Prostate Cancer

November 14th 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

New Approaches to Localized Prostate Cancer Combat Overtreatment

November 14th 2018

Mark Emberton, MD, FRCS, discusses updates in the diagnosis and treatment of patients with localized prostate cancer.

Expert Explains Surgical Considerations in High-Risk Prostate Cancer

November 13th 2018

James Kearns, MD, discusses key issues to consider with surgery in patients with high-risk prostate cancer.

Dr. Emberton Addresses Issues in Diagnosing Localized Prostate Cancer

November 10th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, addresses issues in the diagnosis of localized prostate cancer.

Dr. Tagawa Discusses Radiotherapy in Prostate Cancer

November 8th 2018

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Dr. Burgess on Immunotherapy in Prostate Cancer

November 1st 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the role of immunotherapy in prostate cancer.

Burgess Shares Insight on Evolving Prostate Cancer Paradigm

October 31st 2018

Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.

Dr. Kearns on Choosing Treatment for Patients With Prostate Cancer

October 30th 2018

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses factors to consider when choosing treatment for a patient with prostate cancer.

Darolutamide Improves MFS in Phase III Nonmetastatic CRPC Trial

October 25th 2018

Darolutamide significantly improved metastasis-free survival versus placebo in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Recent Approvals Move Needle for Nonmetastatic CRPC

October 23rd 2018

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.

Dr. Burgess on the Synergy Between Abiraterone and ADT in Prostate Cancer

October 23rd 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the synergy between abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) in prostate cancer.

Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

October 22nd 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC

October 22nd 2018

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden

October 21st 2018

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018